Predictors of Mortality Subsequent to a Fracture in Diabetes Mellitus Patients by Sidse Westberg-Rasmussen et al.
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
ORIGINAL RESEARCH ARTICLE
published: 01 April 2015
doi: 10.3389/fendo.2015.00046
Predictors of mortality subsequent to a fracture in diabetes
mellitus patients
SidseWestberg-Rasmussen1†, Jakob Starup-Linde1,2,3*†, Søren Gregersen1 and PeterVestergaard 2,3
1 Department of Endocrinology and Internal Medicine, Aarhus University Hospital, Aarhus, Denmark
2 Department of Clinical Medicine, Aalborg University, Aalborg, Denmark
3 Department of Endocrinology, Aalborg University, Aalborg, Denmark
Edited by:
Daniela Patrizia Foti, University
“Magna Græcia” of Catanzaro, Italy
Reviewed by:
Elaine Dennison, MRC Lifecourse
Epidemiology Unit, UK
Eusebio Chiefari, University “Magna
Græcia” of Catanzaro, Italy
*Correspondence:
Jakob Starup-Linde, Department of
Endocrinology and Internal Medicine,
Aarhus University Hospital, Tage
Hansens Gade 2, Aarhus C 8000,
Denmark
e-mail: jakolind@rm.dk
†Sidse Westberg-Rasmussen and
Jakob Starup-Linde have contributed
equally to this work.
Background: Type-1 and type-2 diabetes mellitus (DM) are associated with an increased
fracture risk and possibly an increased risk of death following a fracture.
Aim:To investigate the association between diabetes-related drugs and mortality following
a fracture.
Methods: A nested case–control study was conducted. Cases were patients with DM
who died following a fracture; controls were DM patients not dying after a fracture. We
identified DM patients using the Danish National Hospital Discharge Register (1977–2011)
and included information on date of DM diagnosis, date of fracture, and comorbidities.
From the Danish Cause of Death Register, the date of death was collected (2008–2011).
From the Central Region of Jutland, Denmark, medication use was collected (2008–2011).
Analysis was performed by unconditional logistic regression.
Results:Two thousand six hundred twenty one diabetes patients with a fracture following
the diabetes diagnosis and with information on medication use were included. Of these,
229 died. In a multivariate analysis, statin use [n=1,106 (42%) statin users, odds ratio
(OR)=0.60, 95% confidence interval, p=0.012] decreased the risk of dying subsequent
to a fracture. Male gender (OR=1.57, p=0.005), increasing age (OR=1.08, p<0.001), a
diagnosis of retinopathy (OR=2.12, p=0.008), heart failure (OR=1.68, p=0.004), and use
of glucocorticoids (OR=2.22, p=0.001) were associated with an increased risk of death.
None of the antidiabetics: biguanides, glucagon-like receptor agonists, β-cell stimulants,
glitazones, and insulin were associated with mortality.
Conclusion: Co-morbidity reflected by late onset complications, heart failure, and gluco-
corticoid use was associated with an increased risk of mortality subsequent to a fracture.
Statin use may reduce mortality subsequent to a fracture in diabetes patients. Clinical trials
are needed to determine whether diabetes patients with a fracture should initiate statin
treatment.
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INTRODUCTION
Diabetes mellitus (DM) is a common disease, with 382 million
humans affected worldwide (1). The incidence of type-2 DM
(T2DM) is increasing, mirroring the rise in sedentary lifestyle
and obesity, while the incidence of type-1 DM (T1DM) has
remained relatively constant. Hyperglycemia results in the for-
mation of advanced glycated endproducts (AGEs) and oxidative
stress, along with a multitude of other actions. DM is associ-
ated with a series of complications (2). The most important
complications are macrovascular disease, such as atherosclerosis,
and microvascular disease such as retinopathy, nephropathy, and
neuropathy. Recently, another complication has been added to
the list, namely a negative influence on bone (3, 4). The mech-
anism behind the impact of diabetes on bone is still widely
unknown.
Several studies have shown an association between diabetes
and increased risk of fractures (4–6). Furthermore, the use of the
WHO fracture risk assessment tool (FRAX) apparently underesti-
mates the risk of fractures in patients with DM (5). Thus, there is
a need for alternative tools to predict fracture in diabetic patients.
Bone strength depends on both bone quantity and bone quality. As
for bone quantity, T2DM patients have higher bone mineral den-
sity (BMD), which may be due to obesity, whereas T1DM patients
have lower BMD (4). However, the lower BMD in T1DM patients
cannot fully explain the higher incidence of fracture among these
patients. It seems that DM has an effect on bone quality, on a
microarchitectural scale, which leaves bones more porous and
prone to fracture.
Risk of mortality and other adverse events due to fractures seem
higher in diabetics compared to healthy patients (6–8). Huang
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et al. (8) showed that not only did DM patients have a signif-
icantly higher mortality rate due to fracture but they also had
higher readmission rates during the first months following dis-
charge compared to patients without DM. In addition, the DM
patients were less likely to have regained walking ability, general
health, and physical functioning after a year. Liao et al. (6) found
increased mortality rates, higher risk of septicemia, deep wound
infection, and urinary tract infection, after a surgically treated frac-
ture compared with patients without DM. This warrants further
investigations into the predictors of mortality and adverse effects
in diabetics who experience fracture.
The aim of this study is to investigate the association between
diabetes related drugs, comorbidities, and mortality due to
fracture.
MATERIALS AND METHODS
DESIGN
We conducted a nested case–control study in a cohort of DM
patients. Cases were defined as DM patients who died subsequent
to fracture in the period from 01-01-1977 to 31-12-2011. Con-
trols were DM patients who had a fracture, but did not die, in the
same period. We obtained approval by the Danish Data Protection
Agency.
DIABETES, FRACTURE, AND MORTALITY ASSESSMENT
Using the Danish National Hospital Discharge Register (1977–
2011), we included DM patients for whom information on date of
DM diagnosis, date of fracture, and comorbidities was available.
Only patients for whom the fracture occurred after the DM diag-
nosis were included. Date of death was collected from the Danish
Cause of Death Register. Table 1 gives an overview of the exposure
variables applied and corresponding ICD and ATC codes.
MEDICATION USE ASSESSMENT
From the Central Region of Jutland, Denmark, medication use
was collected (2008–2011) by ATC codes (see Table 1). Medica-
tion use was defined as having collected a prescription prior to
fracture. Only data regarding redeemed drugs on prescription and
not over-the-counter drugs were available. In the register, all sales
are registered to the individual who redeems the prescription, and
therefore the validity of data is high.
Medication types included were anti-smoking medication,
antidiabetics; glitazones, biguanides, beta-cell-stimulating med-
ication, glucagon-like peptide (GLP)-1 receptor agonists, and
insulin; antiepileptics, antipsycotics, antidepressants, statins, bone
active drugs, and antihypertensive medication.
PROXY VARIABLES
A proxy variable for smoking (yes/no) was created by drug usage;
yes was defined as use of nicotine substitution, vareniclin, bupro-
pion, inhaled beta-agonists, inhaled anticholinergics, or inhaled
corticosteroids. A proxy variable for hypertension (yes/no) was
created by drug usage; yes was defined as use of diuretics, beta-
blockers, calcium channel antagonists, angiotensin converting
enzyme (ACE) inhibitors/AT2 antagonists, antiadrenergic drugs
with either peripheral or central effect, renin inhibitors, and
hydralazine. A proxy variable for usage of drugs affecting bone
Table 1 | Overview of included variables and respective codes from
ICD or ATC.
Diabetes mellitus and fractures (ICD)
Type-1 diabetes mellitus: DE100, DE101, DE109, 24900, 24909, 24907,
24906
Type 2 diabetes mellitus: DE110, DE111, DE119, 25006, 25007, 25009;
fractures: S02.0–S02.9, S07.0–S07.9, S12.0–S12.9, S22.0–S22.9,
S32.0–S32.8, S42.0–S42.9, S52.0–S52.9, S62.0–S62.9, S72.0–S72.9,
S82.0–S82.9, S92.0–S92.9, 800–808.09, 808.11–808.19, 808.91–816.09,
816.19, 816.99–820.12, 820.18–820.92, 820.98–821.22, 821.28–821.32,
821.38–821.92, 821.98–824.03, 824.08–824.13, 824.18–824.93,
824.98–825.99, 826.01–826.19, 826.99–829.99
Comorbidities (ICD)
AMI (DI21, DI22, DI23, 41009, 41099), nephropathy (DE102, DE112,
24902, 25002), neuropathy (DE104, DE114, 24903, 25003), retinopathy
(DE103, DE113, 24901, 25001), peripheral artery disease (DE105, DE115,
24904, 24905, 25004, 25005), heart failure (DI50, DI110, DI130, DI132,
42709–42711, 42719, 42899), alcohol (DF10, 303)
Antidiabetic drugs, antihypertensive drugs, statins (ATC)
Insulin (A10A), biguanides (A10BA), β-cell stimulating (A10BB), glitazones
(A10BG), GLP-1 receptor agonists (A10BX), antihypertensive drugs (C09,
C07A, C08, C02AB, C02AC, C02CA, C02DB, C03C, C03AA, C03D), statins
(C10AA)
Antiosteoporotic agents (ATC)
Hormone replacement therapy (G03), strontium ranelate (M05BX03),
teriparatide (H05AA), bisphosphonates (M05BA), denosumab (M05BX)
Smoking variable (ATC)
Inhaled steroids (R03BA), vareniclin (N07BA03), nicotine substitution
(N07BA01), bupropion (N06AX12), β2-agonist (R03AC), inhaled
anticholinergics (R03BB)
Others (ATC)
Antipsychotics (N05A), antiepileptics (N03A), antidepressants (N06A),
glucocorticoids (H02AB)
(yes/no) was created by drug usage; yes was defined as the use of
bisphosphonates, teriparatide, strontium ranelate, denosumab, or
hormone replacement therapy (Table 1).
STATISTICAL ANALYSIS
The statistical analyses were conducted using the STATA 8 sta-
tistics package. Pharmaceutical use was handled as (yes/no) and
biochemical markers were handled as numerical values. An unad-
justed case–control analysis and an adjusted case–control analysis
were performed using logistic regression. The adjusted analysis
was performed to address potential confounding. All results are
presented as odds ratios (OR). In the following, the expression
risk will be used synonymously with OR.
RESULTS
SUBJECT CHARACTERISTICS
Two thousand six hundred twenty-one DM patients with a frac-
ture subsequent to diabetes diagnosis and with information on
medication use were included in the study. Of these, 435 had
T1DM, 1,155 had T2DM, and the remaining 1,031 had an unspec-
ified diabetes diagnosis. Baseline characteristics are shown in
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Table 2 | Baseline characteristics of cases and controls.
Variable Total (n=2,621) Cases (n=229) Controls (n=2,392) p-Value
Age (95% CI)a,* 61.9 (61.2–62.6) 75.7 (74.2–77.3) 60.6 (59.8–61.3) <0.001
Diabetes durationa 7.7 (7.5–7.9) 8.1 (7.5–8.6) 7.7 (7.4–7.9) 0.140
Male gender (n, %) 1,226 (46.8) 115 (50.2) 1,111 (46.4) 0.275
Smoking (n, %) 239 (9.1) 20 (8.7) 219 (9.2) 0.832
Alcohol (n, %) 229 (8.7) 21 (9.2) 208 (8.7) 0.808
Nephropathya 226 (8.6) 28 (12.2) 198 (8.3) 0.079
Neuropathy (n, %) 209 (8.0) 19 (8.3) 190 (7.9) 0.850
Retinopathy (n, %)a 191 (7.3) 22 (9.6) 169 (7.1) 0.210
Peripheral artery disease (n, %)a,* 296 (11.3) 42 (18.3) 254 (10.6) 0.004
Acute myocardial infarction (n, %)a,* 334 (12.7) 55 (24.0) 279 (11.7) <0.001
Heart failure (n, %)a,* 334 (12.7) 65 (28.4) 269 (11.2) <0.001
Previous fracture (n, %) 872 (33.3) 71 (31.0) 801 (33.5) 0.447
Insulins (n, %) 887 (33.8) 66 (28.8) 821 (34.3) 0.093
Biguanides (n, %)a,* 723 (27.6) 47 (20.5) 676 (28.3) 0.007
Glitazones (n, %)a 12 (0.5) 2 (0.9) 10 (0.4) 0.471
GLP-1 receptor agonists (n, %)a,* 78 (2.2) 1 (0.4) 77 (3.2) <0.001
β-cell stimulants (n, %) 481 (18.4) 47 (20.5) 434 (18.1) 0.374
Glucocorticoids (n, %)a,* 273 (10.4) 37 (16.2) 236 (9.9) 0.013
Antiepileptics (n, %)a 183 (7.0) 12 (5.2) 171 (7.1) 0.224
Antipsychotics (n, %) 120 (4.6) 9 (3.9) 111 (4.6) 0.623
Antidepressants (n, %) 570 (21.7) 55 (24.0) 515 (21.5) 0.384
Statins (n, %)a 1,106 (42.2) 78 (34.1) 1,028 (43.0) 0.009
Antihypertensives (n, %) 1,387 (52.9) 125 (54.6) 1,262 (52.8) 0.597
Bone active drugs (n, %) 219 (8.4) 17 (7.4) 202 (8.4) 0.594
aBartlett’s test revealed unequal variance, therefore t-test for two samples with unequal variance was performed.
*p<0.05 between cases and controls.
Table 2. When comparing cases with controls, cases were sig-
nificantly older, with a mean age of 75.7 years (95% confidence
interval (CI): 74.2–77.3) compared to 60.6 years (CI: 59.8–61.3)
for controls, and had higher prevalence of cardiovascular disease
including peripheral artery disease (p= 0.004), acute myocar-
dial infarction (p< 0.001), and heart failure (p< 0.001). Cases
had a significantly higher use of glucocorticoids (p= 0.013)
and lower use of biguanides (p= 0.007) and statins (p= 0.009)
compared to controls. Gender, diabetes duration, previous frac-
tures, smoking, and alcohol were not different between cases and
controls.
MORTALITY
Of the 2,621 DM patients, 229 died (8.7%). Table 3 shows the
crude ORs for the cohort of diabetes patients. When no adjust-
ments for various variables were made, age (OR= 1.07,p< 0.001),
nephropathy (OR= 1.54, p= 0.043), peripheral artery disease
(OR= 1.89, p= 0.001), acute myocardial infarction (OR= 2.39,
p< 0.001), heart failure (OR= 3.13, p< 0.001), and glucocor-
ticoid use (OR= 1.76, p= 0.003) were all associated with an
increased risk of death subsequent to a fracture. Biguanides
(OR= 0.66, p= 0.013), GLP-1 receptor agonists (OR= 0.13,
p= 0.045), and statins (OR= 0.69, p= 0.009) were associated
with a lowered risk of death subsequent to a fracture. Gender,
diabetes duration, previous fracture, smoking, and alcohol were
not associated with the risk of death.
Table 4 shows the multivariate analysis for the cohort of dia-
betes patients. In the multivariate analysis, statin use was still
found to be associated with a decreased risk of death subsequent
to a fracture (OR= 0.60, p= 0.012), but the effect of biguanides
and GLP-1 receptor agonists were no longer significant. Male gen-
der (OR= 1.57, p= 0.005), increasing age (OR= 1.08, p< 0.001),
a diagnosis of retinopathy (OR= 2.12, p= 0.008), heart failure
(OR= 1.68, p= 0.004), and use of glucocorticoids (OR= 2.22,
p< 0.001) all increased the risk of death. None of the other
antidiabetics: beta-cell stimulants, glitazones, and insulin, were
significantly associated with mortality.
DISCUSSION
In the multivariate analysis, male gender, increasing age, a diag-
nosis of retinopathy, heart failure, and use of glucocorticoids
increased risk of death following a fracture. A diagnosis of
retinopathy, which is a common complication of diabetes, is asso-
ciated with an increased risk of all-cause mortality and cardiovas-
cular events in both type-1 and type-2 DM (9). The increased risk
of death subsequent to fracture found in patients with retinopathy
is therefore to be expected. Heart failure is an indicator of poor
general health and is in itself associated with increased mortality,
which explains the increased risk of mortality due to fracture; per-
haps especially due to the stress induced by a fracture or perhaps
surgery for the fracture. Chronic use of glucocorticoids increases
the risk of osteoporosis and thereby the risk of fracture. Users
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Table 3 | Crude odds ratios (OR) for death subsequent to a fracture
(n=2,621).
Variable (n) OR (95% CI) p-value
Age (per year)* 1.07 (1.06–1.08) <0.001
Diabetes duration (per year) 1.02 (0.99–1.04) 0.216
Male gender (1,226) 1.16 (0.89–1.53) 0.275
Smoking (239) 0.95 (0.59–1.53) 0.832
Alcohol (229) 1.06 (0.66–1.70) 0.808
Nephropathy* (226) 1.54 (1.01–2.35) 0.043
Neuropathy (209) 1.05 (0.64–1.72) 0.850
Retinopathy (191) 1.40 (0.88–2.23) 0.159
Peripheral artery disease* (296) 1.89 (1.32–2.71) 0.001
Acute myocardial infarction* (334) 2.39 (1.72–3.32) <0.001
Heart failure* (334) 3.13 (2.29–4.28) <0.001
Previous fracture (872) 0.89 (0.67–1.20) 0.446
Insulins (887) 0.77 (0.56–1.04) 0.093
Biguanides* (723) 0.66 (0.47–0.91) 0.013
Glitazones (12) 2.10 (0.46–9.64) 0.340
β cell stimulants (481) 1.17 (0.83–1.63) 0.374
GLP-1 receptor agonists* (78) 0.13 (0.02–0.95) 0.045
Glucocorticoids* (273) 1.76 (1.20–2.57) 0.003
Antiepileptics (183) 0.72 (0.39–1.31) 0.281
Antipsychotics (120) 0.84 (0.42–1.68) 0.624
Antidepressants (570) 1.15 (0.84–1.58) 0.384
Statins* (1,106) 0.69 (0.52–0.91) 0.009
Antihypertensives (1,387) 1.07 (0.82–1.41) 0.597
Bone active drugs (219) 0.87 (0.52–1.45) 0.594
*Significant, i.e., p<0.05 between cases and controls.
of glucocorticoids are often very ill, and glucocorticoid use lowers
immune system capacity, which explains why these patients are less
resistant to complications from fracture, and therefore more likely
to die. Glucocorticoid use may also increase the risk of Addison
crisis following a fracture.
The seemingly protective potential of statins in terms of mor-
tality following a fracture in diabetes patients is a novel and very
interesting finding. Statins are widely used and well accepted as
secondary prevention of cardiovascular events in patients with
previous coronary artery disease, in whom they have been shown
to lower all-cause mortality (10, 11). Statins lower total choles-
terol and low-density-lipoprotein cholesterol in blood (10), which
may retard the progression of coronary atheromatous lesions,
which subsequently leads to a lowered risk of plaque rupture
and thereby coronary events (12). It is debated whether or not
statins should be used for primary prevention, e.g., in people with
known risk factors but with no history of cardiovascular events.
A meta-analysis by Ray et al. (13) found no significant reduc-
tion in all-cause mortality when statins were used as primary
prevention in intermediate to high-risk individuals without a his-
tory of cardiovascular disease. The reduction in mortality due to
fracture found in our study may be a reflection of the general all-
cause mortality lowering effect of statins in patients with previous
cardiovascular disease, or may be due to a direct effect of statins
on bone.
Table 4 | Multivariate adjusted odds ratios (OR) for death subsequent
to a fracture (n=2,621).
Variable (n) OR (95% CI) p-value
Age (per year)* 1.08 (1.07–1.10) <0.001
Diabetes duration (per year) 1.03 (1.00–1.06) 0.088
Male gender* (1,226) 1.57 (1.15–2.15) 0.005
Smoking (239) 0.90 (0.52–1.56) 0.703
Alcohol* (229) 2.29 (1.32–3.97) 0.003
Nephropathy (226) 1.34 (0.83–2.14) 0.228
Neuropathy (209) 0.90 (0.52–1.55) 0.701
Retinopathy* (191) 2.12 (1.22–3.67) 0.008
Peripheral artery disease (296) 1.47 (0.98–2.18) 0.060
Acute myocardial infarction (334) 1.22 (0.84–1.77) 0.307
Heart failure* (334) 1.68 (1.18–2.40) 0.004
Previous fracture (872) 0.87 (0.63–1.21) 0.419
Insulins (887) 1.07 (0.71–1.60) 0.750
Biguanides (723) 1.01 (0.68–1.52) 0.951
Glitazones (12) 3.32 (0.61–18.13) 0.166
β cell stimulants (481) 0.91 (0.60–1.39) 0.676
GLP-1 receptor agonists (78) 0.23 (0.03–1.73) 0.152
Glucocorticoids* (273) 2.22 (1.41–3.49) 0.001
Antiepileptics (183) 0.85 (0.44–1.65) 0.634
Antipsychotics (120) 0.95 (0.44–2.07) 0.904
Antidepressants (570) 1.12 (0.76–1.64) 0.579
Statins* (1,106) 0.60 (0.41–0.90) 0.012
Antihypertensives (1,387) 0.85 (0.54–1.33) 0.472
Bone active drugs (219) 0.83 (0.47–1.47) 0.524
*Significant, i.e., p<0.05.
In the year 2013, The Danish Diabetes Database (14) found that
35% of T2D in outpatient clinics and 46% of T2D in general prac-
tice aged 40 years or more with an LDL cholesterol >2.5 mmol/l
did not receive lipid-lowering drugs as suggested by current guide-
lines. The protective effect of statins present in our study may be
due to treatment following guidelines; however, statins may have
beneficial effects beside what guidelines suggest, as we are not able
to determine the indication of treatment versus non-treatment.
Statin use may also affect the risk of fracture by a direct effect
on bone. Many studies have investigated the effect of statins on
fracture risk, with some pointing toward a protective effect (15–
17) and some pointing toward no effect (18, 19). A meta-analysis
from 2007 by Toh et al. (18) found that current evidence does
not support an effect of statins in preventing fractures, as there
is a lack of association in randomized trials, high heterogeneity
among observational studies, and potential residual confounding
and publication bias. There has been a lot of debate on the potential
“healthy drug user effect,” which suggests that the reason for lower
fracture rates among statin users is caused by statin users being
more frequent users of medical services and therefore healthier
and more aware of healthy behavior. If this was the case, use of
other lipid-lowering drugs would be expected to have the same
fracture risk-lowering effect. A nation-wide case–control study by
Rejnmark et al. (16) showed that non-statin lipid-lowering drugs
did not decrease fracture risk, while statins did. This argues against
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a healthy drug user effect and points toward an actual fracture
risk-lowering effect of statins. If statins, as suggested, are protec-
tive against fractures only individuals with severely reduced bone
status and possibly the most ill have fractures when using statins.
This supports the association seen in our study. Thus, statins may
both decrease the risk of fracture and decrease the risk of mor-
tality. However, we cannot completely rule out the “healthy drug
user effect.”
The suggested biological mechanisms underlying the effect of
statins on bone are numerous. Statins competitively inhibit HMG-
CoA reductase, which is the rate-limiting enzyme in the pathway
that produces cholesterol. One of the other metabolites in this
pathway, whose synthesis is also inhibited by statin treatment,
is farnesyl pyrophosphate (FPP). FPP inhibits osteoblast differ-
entiation. Thus blockage of FPP synthesis may induce increased
osteoblast formation and osteogenesis (20). Another mechanism
may be via an effect on the estrogen receptor-alpha (ER-α).
Estrogen is an important anabolic factor in bones, and post-
menopausal women with lower estrogen levels are more prone
to osteoporosis than men and premenopausal women. The effect
of estrogen on bone is primarily exerted through the ER-α. Song
et al. (21) reported that simvastatin increases the expression of
ER-α in murine osteoprecursor cells. This was confirmed in a
follow-up study, which also found increased ER-α in ovariec-
tomized rats treated with simvastatin (22). Increased ER-α could
lead to an increased sensitivity to the anabolic influence of estro-
gen on bone. Finally, another possible mechanism may be that
statins increase osteoblastic differentiation through enhancement
of bone morphogenetic protein-2 (BMP-2) mRNA expression.
This effect was seen in murine non-transformed osteoblastic
cells and rat bone marrow cells (23). If these biological mech-
anisms are present in humans, statin use may entail increased
fracture healing and thereby increased survival rates, which partly
may explain the positive effect of statins on mortality follow-
ing a fracture. However, further studies are warranted, in order
to make conclusions about the above-mentioned pathways in
humans.
The strengths of this study are the large group of diabetes
patients and the validity of the data registries. This enabled us
to make adjustments for numerous variables. We cannot know
whether patients actually complied with the medications col-
lected at the pharmacy; however, there is a good chance that
patients were motivated to use them, as they collected and paid for
them. Our subjects were all Danish citizens. Denmark has a free
healthcare system and subsidies are given for prescription drugs.
This secures an equal distribution of our subjects among social
classes.
This is a retrospective case–control study, which has certain lim-
itations. As different physicians throughout Denmark collected the
data used in our study, i.e., diagnosed patients, we rely on other
people’s professional, but never the less subjective, opinions. If a
physician failed to report symptoms, diagnoses, or outcomes, we
have no way of controlling data. Not all diabetes diagnoses were
sub-classified as type-1 or type-2 DM. We have no measurements
of weight and height and therefore adjustment for BMI was not
possible. Furthermore, we did not have actual data on smoking,
but used a proxy constructed from diagnoses and drug use known
to be associated with smoking. However, the proxy variable for
smoking was not associated with mortality, which may question
the precision.
CONCLUSION
Co-morbidity reflected by late onset complications, heart failure,
and glucocorticoid use were associated with an increased risk of
mortality subsequent to fracture in diabetes patients. Statin use
may reduce mortality subsequent to fracture in diabetes. Clini-
cal trials should decide whether diabetes patients suffering from
a fracture should start statin treatment irrespective of current
recommendations.
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